company background image
MRNA logo

Moderna NasdaqGS:MRNA Stock Report

Last Price

US$44.26

Market Cap

US$16.6b

7D

1.4%

1Y

-44.6%

Updated

02 Dec, 2024

Data

Company Financials +

MRNA Stock Overview

A biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More details

MRNA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for MRNA from our risk checks.

Moderna, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Moderna
Historical stock prices
Current Share PriceUS$44.26
52 Week HighUS$170.47
52 Week LowUS$35.80
Beta1.69
11 Month Change-18.98%
3 Month Change-39.32%
1 Year Change-44.59%
33 Year Change-83.32%
5 Year Change135.68%
Change since IPO137.96%

Recent News & Updates

Here's Why We're Watching Moderna's (NASDAQ:MRNA) Cash Burn Situation

Nov 30
Here's Why We're Watching Moderna's (NASDAQ:MRNA) Cash Burn Situation

Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store

Nov 22

Recent updates

Here's Why We're Watching Moderna's (NASDAQ:MRNA) Cash Burn Situation

Nov 30
Here's Why We're Watching Moderna's (NASDAQ:MRNA) Cash Burn Situation

Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store

Nov 22

Moderna: Assessing The Impact Of GSK's Patent Lawsuit

Oct 22

The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Oct 11
The Market Doesn't Like What It Sees From Moderna, Inc.'s (NASDAQ:MRNA) Revenues Yet As Shares Tumble 28%

Moderna: Still Bullish View

Sep 20

Moderna: Fresh Sell-Off On Cost Cutting Initiatives, Short-Term Outlook Troubling

Sep 12

Moderna's Vaccine Progress Undermined By RSV Market Contraction (Rating Downgrade)

Aug 26

Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Aug 18
Lacklustre Performance Is Driving Moderna, Inc.'s (NASDAQ:MRNA) 28% Price Drop

Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Aug 03
Analysts Have Lowered Expectations For Moderna, Inc. (NASDAQ:MRNA) After Its Latest Results

Moderna: State Of Play Ahead Of Q2 Earnings, I'm (Temporarily) Pessimistic

Jul 30

Moderna: Really Strong Competition

Jun 30

Moment Of Truth Approaches For Moderna's RSV Vaccine

Jun 18

What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Jun 06
What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

May 23

Moderna Q1: A Promising Pipeline Is Undervalued

May 15

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30
We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Apr 22
Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Moderna: Considering The Cancer Vaccine Angle

Apr 11

Moderna Continues To Build A Pipeline

Apr 03

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Mar 27

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27
Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Shareholder Returns

MRNAUS BiotechsUS Market
7D1.4%0.8%0.7%
1Y-44.6%15.0%32.2%

Return vs Industry: MRNA underperformed the US Biotechs industry which returned 15% over the past year.

Return vs Market: MRNA underperformed the US Market which returned 32.2% over the past year.

Price Volatility

Is MRNA's price volatile compared to industry and market?
MRNA volatility
MRNA Average Weekly Movement8.0%
Biotechs Industry Average Movement9.9%
Market Average Movement6.3%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stable Share Price: MRNA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MRNA's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20105,600Stephane Bancelwww.modernatx.com

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.

Moderna, Inc. Fundamentals Summary

How do Moderna's earnings and revenue compare to its market cap?
MRNA fundamental statistics
Market capUS$16.57b
Earnings (TTM)-US$2.22b
Revenue (TTM)US$5.08b

3.4x

P/S Ratio

-7.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRNA income statement (TTM)
RevenueUS$5.08b
Cost of RevenueUS$6.48b
Gross Profit-US$1.40b
Other ExpensesUS$824.00m
Earnings-US$2.22b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-5.78
Gross Margin-27.55%
Net Profit Margin-43.77%
Debt/Equity Ratio0%

How did MRNA perform over the long term?

See historical performance and comparison